Lilly's fourth quarter revenue reached $19.29 billion, up 42.6% year-over-year, powered almost entirely by two products. Mounjaro generated $7.41 billion, up 110%, while Zepbound added $4.26 billion, up 123%.
Antibiotics are essential for modern medicine, but bacteria are evolving and developing resistance, turning routine infections into life-threatening conditions. A global analysis estimates that antibiotic-resistant infections could cause over 39 million deaths by 2050.
Ushering in the Golden Age of Innovation is about more than just winning the global tech race - it's about securing the safety and prosperity of our country for generations to come. Our bill is an important step in this effort and will better ensure the United States has the infrastructure in place to lead the 21st century.
According to the patent, a specific crystalline form of the drug known as polymorph C may be more effective than other versions because it is absorbed more efficiently by the body. The patent also notes that laboratory studies showed the drug reduced tumor growth and helped mice with brain tumors live longer, prompting early clinical trials to test whether the treatment is safe and effective in humans.
The Food and Drug Administration granted expedited approval to orforglipron, a GLP-1 drug that works like widely used injectable medications to mimic a natural hormone that controls appetite and feelings of fullness.
RBC Capital analyst Luca Issi upgraded the stock to Outperform from Sector Perform with a price target of $35, up from $11. Wells Fargo also upgraded uniQure to Overweight from Equal Weight with a $60 price target. The catalyst: the departure of Vinay Prasad from the FDA. RBC views this as a positive for uniQure, noting it is "not inconceivable" that the FDA reverts to its prior stance, and believes Prasad's departure is likely to open up a more balanced discussion on risk/reward for Huntington's disease.
Emma Dyer remembers the moment she clicked "buy now" on a set of weightloss jabs she found online. She had no medical consultation, no ID checks, and no questions about her history of anorexia and bulimia. "It was just so easy - too easy," she says. "They never asked for my medical history or what medication I was taking. It was like buying groceries."
In children below the age of five, whose immune systems are still developing, the infections can lead to malnourishment; they cause up to 42,000 deaths annually. Soon there may be a vaccine to protect against these infections. In the Lancet Infectious Diseases last month, scientists shared the results of the first study to evaluate the safety and efficacy of an ETEC-controlling vaccine in a large pediatric population in Gambia.
"I was involuntarily undressed by Elon Musk's Grok on X," Swedish Deputy Prime Minister Ebba Busch said in a recent video on the platform. She is one of countless victims of a feature on X's AI chatbot, Grok, that allows users to digitally strip women and children of their clothing. In less than two weeks, Grok generated three million sexualized images, including tens of thousands that appear to depict children.
The U.S. Food and Drug Administration is reportedly mulling whether more prescription drugs should be sold over the counter (OTC) at pharmacies. In an interview on Wednesday, FDA commissioner Martin Makary told CNBC that everything should be over the counter except drugs that are deemed unsafe or addictive or that require clinical monitoring. Makary said the agency is reviewing how it decides which drugs can be sold with or without a prescription from a health care practitioner.
The European Parliament has taken a rare and telling step: it has disabled built-in artificial intelligence features on work devices used by lawmakers and staff, citing unresolved concerns about data security, privacy, and the opaque nature of cloud-based AI processing. The decision, communicated to Members of the European Parliament (MEPs) in an internal memo this week, reflects a deepening unease at the heart of European institutions about how AI systems handle sensitive data.
Last November, the UK government announced a bold plan to phase out animal testing in some areas of research. Animal tests for skin irritation are scheduled for elimination this year, and some studies on dogs should be slashed by 2030. The long-term vision is 'a world where the use of animals in science is eliminated in all but exceptional circumstances'.
This week in Other Barks & Bites, IPWatchdog's IP news roundup: the House of Representatives passes drug patent legislation, while antitrust legislation targeting patent-related activities is introduced into the Senate and the Trump administration mandates pricing information for pharmaceutical ads; the Patent Trial and Appeal Board (PTAB) issues a pair of precedential decisions on cases with multiple petitions; the USPTO issues marijuana-related trademark guidelines and a notice on modifying patent term adjustment practices;
While the move came as a surprise to the high-profile vaccine maker, it is just the latest hostility toward vaccines-and mRNA vaccines in particular-from an agency overseen by the fervent anti-vaccine activist Robert F. Kennedy Jr. In his first year in office, Kennedy has already dramatically slashed childhood vaccine recommendations and canceled $500 million in research funding for mRNA vaccines against potential pandemic threats.
Health authorities in Spain's Basque Country have launched an investigation after expired doses of the childhood hexavalent vaccine were administered to 253 patients, mostly infants. Osakidetza, the Basque public health service responsible for delivering healthcare across the region, began contacting the affected families this week. The issue was detected on January 15, the agency said in a statement on Wednesday.
Prasad's tenure was generally marked by controversy, but he is departing amid a cluster of self-destructive decisions. Those include a shocking rejection of an mRNA vaccine (which was over the objections of agency scientists and quickly reversed); a demand for an additional clinical trial on a gene therapy for Huntington's disease, which was widely seen as moving the goalpost for the therapy; his startling choice to publicly attack the maker of that gene therapy, UniQure; and alleged abuse of FDA staff, who say he created a toxic work environment.
We provide thought partnership. When a company is developing a drug, there's a lot of work involved, such as understanding the science, designing a study and generating good data. We come in and explain what the standard of care looks like today for their patient population, and what we think it will look like in five to eight years or whenever they plan to launch their therapy.
Many researchers are surprised and relieved over an unusual step taken by the US National Institutes of Health (NIH): the agency is rolling back the red tape on a host of basic-science experiments that involved human participants and had been classified as clinical trials. The decision, which was announced on 29 January and is part of a broader NIH effort to reduce administrative burden, should free such research from the heavy bureaucratic requirements that are designed for clinical trials but are sometimes ill-suited to other fields, such as basic psychology and behavioural studies.
